Skip to main content

What the FDA labels say about taking them together

Rifampin and selegiline

Selegiline's FDA label (Zelapar) of June 1, 2021 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name selegiline.

Check it at the source: the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.); the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.).

What does the rifampin label say about selegiline?

Rifampin's label (effective February 11, 2026) does not name selegiline in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

What does the selegiline label say about rifampin?

Zelapar label (Bausch Health US, LLC, June 1, 2021), drug interactions

Drugs that induce CYP3A4 (e.g., phenytoin, carbamazepine, nafcillin, phenobarbital, and rifampin) should be used with caution.

Source: FDA drug label (Zelapar, NDA021479), Bausch Health US, LLC, effective June 1, 2021 (SPL set 380d7717-2a79-42f3-a712-efe5e7696ba0), via openFDA

Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

13Rifampin generic labelers
11Selegiline generic labelers
RifampinSelegiline
Labeled forn/aParkinson's disease, Depression
Boxed warningNoNo
Pharmacy cost (NADAC)$0.679 per capsule 300 mg capsule$0.756 per capsule 5 mg capsule
Shortage nowIn shortageNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?